Ключевые слова
Как цитировать
Аннотация
В данной публикации представлены результаты II Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2025», который продолжает традицию углубленного обсуждения актуальных и спорных вопросов, возникающих в клинической практике. Под председательством члена-корреспондента РАН, профессора Владимира Федоровича Семиглазова в консенсусе приняли участие ведущие эксперты в области диагностики, хирургии, лучевой терапии и системного лечения рака молочной железы. Эксперты обсудили и проголосовали по 60 ключевым вопросам, касающимся как ранних стадий заболевания, так и метастатического рака молочной железы. Результаты консенсуса обеспечат необходимую основу для дальнейшего совершенствования клинической практики и разработки рекомендаций, направленных на улучшение лечения и качества жизни пациентов с данным заболеванием. Проведение III Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2026» запланировано на 4 июля 2026 г.
Библиографические ссылки
Banys-Paluchowski M., Hartmann S., de Boniface J., et al. Marking techniques for target lymph nodes in node-positive breast cancer treated with neoadjuvant therapy in the AXSANA/EUBREAST-03/AGO-B-053 study (NCT04373655). J Clin Oncol. 2026; 44(7): 575-585.-DOI: https://doi.org/10.1200/JCO.2025.43.16_suppl.503.
Morrow M., Van Zee K.J., Solin L.J., et al. Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol. 2016; 23: 3801–3810.-DOI: https://doi.org/10.1245/s10434-016-5449-z.
Buchholz T.A., Somerfield M.R., Griggs J.J., et al. Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology consensus guideline. J Clin Oncol. 2014; 32(14): 1502-1506.-DOI: https://doi.org/10.1200/JCO.2014.55.1572.
Ассоциация онкологов России, Общероссийская общественная организация «Российское общество клинической онкологии», Общероссийская общественная организация «Российское общество онкомаммологов». Клинические рекомендации: «Рак молочной железы». Ассоциация Онкологов России. 2021; 197.-URL: https://oncology-association.ru/wp-content/uploads/2021/02/rak-molochnoj-zhelezy-2021.pdf. [Association of Oncologists of Russia, All-Russian public organization “Russian Society of Clinical Oncology”, All-Russian public organization “Russian Society of Oncomammologists”. Clinical guidelines: Breast Cancer. Association of Oncologists of Russia. 2021; 197.-URL: https://oncology-association.ru/wp-content/uploads/2021/02/rak-molochnoj-zhelezy-2021.pdf (In Rus)].
Landercasper J., Borgert A.J., Fayanju O.M., et al. Factors associated with reoperation in breast-conserving surgery for cancer: A prospective study of American Society of Breast Surgeon Members. Ann Surg Oncol. 2019; 26(10): 3321-3336.-DOI: https://doi.org/10.1245/s10434-019-07547-w.
McCahill L.E., Single R.M., Aiello Bowles E.J., et al. Variability in reexcision following breast conservation surgery. JAMA. 2012; 307(5): 467-475.-DOI: https://doi.org/10.1001/jama.2012.43.
Зикиряходжаев, А.Д., Волченко Н.Н., Рассказова Е.А., et al. Тактика лечения больных раком молочной железы после органосохраняющих операций при положительных краях резекции R1. Вопросы онкологии. 2020; 66(3), 262–269.-DOI: https://doi.org/10.37469/0507-3758-2020-66-3-262-269. [Zikiryakhodjaev A.D. Volchenko N.N., Rasskazova E.A., et al. Treatment options of breast cancer patients after breast-conserving surgery with positive margins R1. Voprosy Onkologii = Problems in Oncology. 2020; 66(3), 262–269.-DOI: https://doi.org/10.37469/0507-3758-2020-66-3-262-269 (In Rus)].
Рассказова Е.А., Зикиряходжаев А.Д., Волченко Н.Н., Хакимова Ш.Г. Края резекции R1 после органосохраняющих/онкопластических операций у больных раком молочной железы. Опухоли женской репродуктивной системы. 2021; 17(1): 12-19.-DOI: https://doi.org/10.17650/1994-4098-2021-17-1-12-19. [Rasskazova E.A., Zikiryakhodzhaev A.D., Volchenko N.N., Khakimova Sh.G. R1 resection margin after organ-sparing / oncoplastic surgeries for breast cancer. Opukholi zhenskoy reproduktivnoy systemy = Tumors of Female Reproductive System. 2021; 17(1): 12-19.-DOI: https://doi.org/10.17650/1994-4098-2021-17-1-12-19 (In Rus)].
Криворотько П.В., Бондарчук Я.И., Комяхов А.В., et al. Контроль краев резекции при органосохраняющих и онкопластических операциях. Вопросы онкологии. 2024; 70(1): 96–104.-DOI: https://doi.org/10.37469/0507-3758-2024-70-1-96-104. [Krivorotko P.V., Bondarchuk Ya.I., Komyakhov A.V., et al. Control of resection margins during breast-conserving and oncoplastic surgeries. Voprosy Onkologii = Problems in Oncology. 2024; 70(1): 96–104.-DOI: https://doi.org/10.37469/0507-3758-2024-70-1-96-104 (In Rus)].
Lyman G.H., Somerfield M.R., Bosserman L.D., et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017; 35(5): 561-564.-DOI: https://doi.org/10.1200/JCO.2016.71.0947.
Krag D.N., Anderson S.J., Julian T.B., et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010; 11(10): 927-933.-DOI: https://doi.org/10.1016/S1470-2045(10)70207-2.
Giuliano A.E., Ballman K.V., McCall L., et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017; 318(10): 918-926.-DOI: https://doi.org/10.1001/jama.2017.11470.
Seenu V., Mathur S., Suhani, et al. Combined frozen section and imprint smear assessment of sentinel node improves accuracy and reduces false negative rates in breast cancer: A prospective study. Indian J Surg. 2022; 84(3): 335–339.-DOI: https://doi.org/10.1007/s12262-021-02877-0.
Reimer T., Stachs A., Veselinovic K., et al. Axillary surgery in breast cancer — primary results of the INSEMA trial. N Eng J Med. 2025; 392: 1051-1064.-DOI: https://doi.org/10.1056/NEJMoa2412063.
Park K.U., Somerfield M.R., Anne N., et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025; 43(14): 1720-1741.-DOI: https://doi.org/10.1200/JCO-25-00099.
The American Society of Breast Surgeons. Performance and practice guidelines for breast cancer surgery. Breast-Conserving Surgery/Partial Mastectomy. 2018 ; 4.-URL: https://www.breastsurgeons.org/docs/statements/asbrs-breast-conserving-surgery-partial-mastectomy.pdf.
Lester S.C., Bose S., Chen Y.Y., et al. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. College of American Pathologists. 2024; 1-44.-DOI: http://doi.org/10.5858/133.10.1515.-URL: https://documents.cap.org/protocols/Breast.Invasive_4.10.0.0.REL.CAPCP.pdf.
Moran M.S., Schmitt S.J., Giuliano A.E., et al. Society of Surgical Oncology – American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol. 2014; 21(3): 704-716.-DOI: https://doi.org/10.1245/s10434-014-3481-4.
Mamounas E.P., Bandos H., White J.R., et al. Omitting regional nodal irradiation after response to neoadjuvant chemotherapy. N Engl J Med. 2025; 392: 2113-2124.-DOI: https://doi.org/10.1056/NEJMoa2414859.
Groheux D., Vaz S.C., Poortmans P., et al. Role of [18F] FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines. Breast. 2024; 78: 103806.-DOI: https://doi.org/10.1016/j.breast.2024.103806.
Curigliano G., Burstein H.J., Gnant M., et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2021. Ann Oncol. 2021; 32(9): 1216-1235.-DOI: https://doi.org/10.1016/j.annonc.2021.06.023.
Blum J.L., Flynn P.J., Yothers G., et al. Anthracyclines in early breast cancer: The ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017; 35(23): 2647-2655.-DOI: https://doi.org/10.1200/JCO.2016.71.4147.
Henderson I.C., Berry D.A., Demetri G.D., et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003; 21(6): 976-983.-DOI: https://doi.org/10.1200/JCO.2003.02.063.
Mamounas E.P., Bryant J., Lembersky B.C., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol. 2005; 23(16): 3686-3696.-DOI: https://doi.org/10.1200/JCO.2005.10.517.
Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21(7): 1431-1439.-DOI: https://doi.org/10.1200/JCO.2003.09.081.
Hortobagyi G.N., Lacko A., Sohn J., et al. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: Final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025; 36(2): 149-157.-DOI: https://doi.org/10.1016/j.annonc.2024.10.015.
Johnston S.R.D., Toi M., O'Shaughnessy J., et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023; 24(1): 77-90.-DOI: https://doi.org/10.1016/S1470-2045(22)00694-5.
Johnston S.R.D., Toi M., O'Shaughnessy J., et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2024; 35(1): 77-86.-DOI: https://doi.org/10.1016/j.annonc.2023.10.122.
Lobo-Martins S., Arecco L., Cabral T.P., et al. Extended adjuvant endocrine therapy in early breast cancer: Finding the individual balance. ESMO Open. 2025; 10(5): 105057.-DOI: https://doi.org/10.1016/j.esmoop.2025.105057.
Queen Mary University of London. CTS5 Calculator: About.-URL: https://cts5-calculator.com/about.
Verma R., Chandarana M., Barrett J., et al. Post-mastectomy radiotherapy for women with early breast cancer and one to three positive lymph nodes. Cochrane Database Syst Rev. 2023 Jun 16; 6(6): CD014463.-DOI: https://doi.org/10.1002/14651858.CD014463.pub2
Poortmans P.M., Weltens C., Fortpied C., et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015; 373(4): 317-327.-DOI: https://doi.org/10.1056/NEJMoa1415369.
van Maaren M.C., de Munck L., de Bock G.H., et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019; 144(2): 263-272.-DOI: https://doi.org/10.1002/ijc.31914.
Wang J., Wang J., Li Q., et al. Locoregional recurrence risk for breast cancer patients with T1-2 and 1-3 positive lymph nodes receiving modern systemic therapy without postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2022; 112(1): 131-140.-DOI: https://doi.org/10.1016/j.ijrobp.2021.08.031.
Brunt A.M., Haviland J.S., Wheatley D.A., et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet. 2020; 395(10237): 1613-1626.-DOI: https://doi.org/10.1016/S0140-6736(20)30932-6.
Haviland J.S., Owen J.R., Dewar J.A., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14(11): 1086-1094.-DOI: https://doi.org/10.1016/S1470-2045(13)70386-3.
Kim D.Y, Park E., Heo C.Y., et al. Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis. The Breast. 2021; 55: 37-44.-DOI: https://doi.org/10.1016/j.breast.2020.11.020.
Rakhra H., Bane A., Yeung M., et al. Hypofractionated radiation therapy for breast cancer with immediate implant-based reconstruction: A systematic review. Pract Radiat Oncol. 2021; 11(4): 251-261.-DOI: https://doi.org/10.1016/j.prro.2021.02.009.
Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017; 376(22): 2147-2159.-DOI: https://doi.org/10.1056/NEJMoa1612645.
van Ramshorst M.S., van der Voort A., van Werkhoven E.D., et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018: 19(12): 1630-1640.-DOI: https://doi.org/10.1016/S1470-2045(18)30570-9.
Gianni L., Pienkowski T., Im Y.H., et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016; 17: 791-800.-DOI: https://doi.org/10.1016/S1470-2045(16)00163-7.
von Minckwitz G., Procter M., de Azambuja E., et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017; 377(2): 122-131.-DOI: https://doi.org/10.1056/NEJMoa1703643.
Caudle A.S., Kuerer H.M., Le-Petross H.T., et al. Impact of identification of clinically node-negative patients after neoadjuvant chemotherapy on the likelihood of conformational breast conservation surgery. Ann Surg Oncol. 2016; 23: 669-675. Suppl 5.-DOI: https://doi.org/10.1245/s10434-016-5574-8.
Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet. 2010; 375 (9712): 377-384.-DOI: https://doi.org/10.1016/S0140-6736(09)61964-4.
Geyer C.E. Jr., Untch M., Huang C.S., et al. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. N Engl J Med. 2025; 392(3): 249-257.-DOI: https://doi.org/10.1056/NEJMoa2406070.
Pagani O., Walley B.A., Fleming G.F., et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol. 2023; 41(7): 1376-1382.-DOI: https://doi.org/10.1200/JCO.22.01064.
NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment: Breast, ovarian, pancreatic, and prostate. Version 2.2026.-URL: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
Akkoc Mustafayev F.N., Shukla M.A., Lanier A., et al. Survival outcomes of patients with HER2/neu-positive breast cancer with germline BRCA mutations. Cancer. 2024; 130(9): 1600-1608.-DOI: https://doi.org/10.1002/cncr.35159.
Forester E., Belsare A., Kim D.W., et al. What proportion of BRCA-associated breast cancer is human epidermal growth factor 2-low and eligible for additional targeted therapy? J Surg Res. 2024; 299: 217-223.-DOI: https://doi.org/10.1016/j.jss.2024.04.032.
Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(3): 188-194.-DOI: https://doi.org/10.1093/jnci/dji021.
Choong G.M.Y., Yeong J., Lim J.X., et al. The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10 %) early-stage breast cancer. J Clin Oncol. 2024; 42(16): 513.-DOI: https://doi.org/10.1200/JCO.2024.42.16_suppl.513.
Vetter M., Fokas S., Biskup E., et al. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget. 2017; 8(43): 75617-75626.-DOI: https://doi.org/10.18632/oncotarget.18118.
Schmid P., Cortes J., Pusztai L., et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382(9): 810-821.-DOI: https://doi.org/10.1056/NEJMoa1910549.
Cardoso F., Paluch-Shimon S., Senkus E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020; 31(12) 1623-1649.-DOI: https://doi.org/10.1016/j.annonc.2020.09.010.
Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405-424.-DOI: https://doi.org/10.1038/gim.2015.30.
Garber J., Cameron D., Campbell C., et al. OlympiA: Phase 3, multicenter, randomized placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer [Abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024. Clin Cancer Res. 2025; 31 (12 Suppl): Abstract nr GS1-09.-DOI: https://doi.org/10.1158/1557-3265.SABCS24-GS1-09.
Yadav S., Boddicker N. J., Na J., et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023; 41(9): 1703-1713.-DOI: https://doi.org/10.1200/JCO.22.01239.
Mavaddat N., Peock S., Frost D., et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inste. 2013; 105(11): 812-822.-DOI: https://doi.org/10.1093/jnci/djt095.
Makhnoon S., Shirts B.H., Bowen D.J. Clinical implications of variants of uncertain significance on management and outcomes of patients with breast cancer. Genet Med. 2021; 23(12): 2329-2337.-DOI: https://doi.org/10.1038/s41436-021-01284-w.
Mersch J., Brown N., Pirzadeh-Miller S., et al. Prevalence of variant reclassification following hereditary cancer genetic testing. JAMA. 2018; 320(12): 1266-1274.-DOI: https://doi.org/10.1001/jama.2018.13152.
O'Neill S.C., Rini C., Goldsmith R.E., et al. Psychological impact of receiving a variant of uncertain significance result from hereditary cancer genetic testing. Genet Med. 2020; 22(7): 1193-1201.-DOI: https://doi.org/10.1038/s41436-020-0785-6.
Tung N.M., Robson M.E., Ventz S., et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020; 38(36): 4274-4282.-DOI: https://doi.org/10.1200/JCO.20.02151.
Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment–associated cognitive change: An update on the state of the science. J Clin Oncol. 2012; 30(30): 3675–3686.-DOI: https://doi.org/10.1200/JCO.2012.43.0116.
Biganzoli L., Wildiers H., Oakman C., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012; 13(4):e148-e160.-DOI: https://doi.org/10.1016/S1470-2045(11)70383-7.
Rugo H.S., Turner N.C., Finn R.S., et al. Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: A pooled analysis of randomised PALOMA clinical studies. Eur J Cancer. 2018; 101: 123-133.-DOI: https://doi.org/10.1016/j.ejca.2018.05.017.
Goetz M.P., Okera M., Wildiers H., et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021; 186(2): 417-428.-DOI: https://doi.org/10.1007/s10549-020-06029-y.
André F., et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019; 380(20): 1929–1940.-DOI: https://doi.org/10.1056/NEJMoa1813904.
Turner N.C., Oliveira M., Howell S.J., et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023; 388(22): 2058-2070.-DOI: https://doi.org/10.1056/NEJMoa2214131.
Nader-Marta G., Tolaney S.M., Mayer E.L. Inavolisib-based triplet therapy for PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. JCO Oncol Pract. 2025; 2(1): 1-5.-DOI: https://doi.org/10.1200/OA-25-00041.
Paluch-Shimon S., Cardoso F., Partridge A.H., et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer: Hereditary breast and ovarian cancer. Ann Oncol. 2023; 34(1): 20-32.-DOI: https://doi.org/10.1016/j.annonc.2022.10.004.
Brufsky A.M., Mayer M., Rugo H.S., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011; 17(14): 4834-4843.-DOI: https://doi.org/10.1158/1078-0432.CCR-10-2962.
Amir E., Miller N., Geddie W., et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012; 30(6): 587–592.-DOI: https://doi.org/10.1200/JCO.2010.33.5232.
Nakatani S., Hayashi T., Hosaka A., Maeda H. Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2026; 217: 105016.-DOI: https://doi.org/10.1016/j.critrevonc.2025.105016.
Божок А.А., Топузов Э.Э., Зикиряходжаев А.Д., et al. Оценка результатов НИР РООМ «Возможности хирургического лечения больных раком молочной железы IV стадии». Опухоли женской репродуктивной системы. 2016; 4(4): 17–24.-DOI: https://doi.org/10.17650/1994-4098-2016-12-4-17-24. [Bozhok A.A., Topuzov E.E., Zikiryakhodzhaev A.D, et al. Evaluation of the scientific results of the study entitled “Opportunities for surgical treatment of patients with stage IV breast cancer” performed by Russian Society of Oncomammologists (RSOM). Tumors of Female Reproductive System. 2016; 4(4): 17–24.-DOI: https://doi.org/10.17650/1994-4098-2016-12-4-17-24 (In Rus)].
André F., Cortés J., Curigliano G., et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 2024; 35(12): 1169-1180.-DOI: https://doi.org/10.1016/j.annonc.2024.08.2347.
Lin N.U., Claus E., Sohl J., et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer. 2008; 113(10): 2638-2645.-DOI: https://doi.org/10.1002/cncr.23930.
Золотой стандарт профилактики, диагностики, лечения и реабилитации больных РМЖ. 2026; 309. Российское общество онкомаммологов.-URL: https://docs.google.com/document/d/14XU19rSHmmg0v8aL9msY9B1uoscVK7WS/edit#heading=h.gjdgxs. [Gold standard of prevention, diagnosis, treatment and rehabilitation of patients with breast cancer. 2026; 309. Russian Society of Oncomammologists.- URL: https://docs.google.com/document/d/14XU19rSHmmg0v8aL9msY9B1uoscVK7WS/edit#heading=h.gjdgxs (In Rus)].
Robson M., Im S.A., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377(6): 523-533.-DOI: https://doi.org/10.1056/NEJMoa1706450.
Tung N.M., Robson M.E., Ventz S., et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 2020; 38(36): 4274-4282.-DOI: https://doi.org/10.1200/JCO.20.02151.
Han Y., Wang J., Xu B. Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis. The Breast. 2020; 54: 114–120.-DOI: https://doi.org/10.1016/j.breast.2020.09.006.
Mohammed A.A. The clinical behavior of different molecular subtypes of breast cancer. Cancer Treat Res Commun. 2021; 29: 100469.-DOI: https://doi.org/10.1016/j.ctarc.2021.100469.
van der Heiden-van der Loo M., Schaapveld M., Ho V.K.Y., et al. Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes. Ann Oncol. 2013; 24(11): 2794–2801.-DOI: https://doi.org/10.1093/annonc/mdt243.
Pareja F., Ferrando L., Lee S.S.K., et al. The genomic landscape of metastatic histologic special types of invasive breast cancer. Breast Cancer. 2020; 6: 53.-DOI: https://doi.org/10.1038/s41523-020-00195-4.
Кудайбергенова А.Г., Семиглазова Т.Ю., Понасенко О.И., et al. Особые гистологические типы рака молочной железы. Неблагоприятный прогноз. Вопросы онкологии. 2025; 71(3): OF–2408.-DOI: https://doi.org/10.37469/0507-3758-2025-71-3-OF-2408. [Kudaibergenova A.G., Semiglazova T.Yu., Ponasenko O.I., et al. Special histological types of breast cancer. Favorable prognosis. Voprosy Onkologii = Problems in Oncology. 2025; 71(3): OF–2408.-DOI: https://doi.org/10.37469/0507-3758-2025-71-3-OF-2408 (In Rus)].
Yang L.-P., Sun H.-F., Zhao Y., et al. Clinicopathological characteristics and survival outcomes in pleomorphic lobular breast carcinoma of the breast: a SEER population-based study. Cancer Med. 2017; 6(12): 2867–2875.-DOI: https://doi.org/10.1002/cam4.1244.
Yamauchi H., Woodward W.A., Valero V., et al. Inflammatory breast cancer: What we know and what we need to learn. The Oncologist. 2012; 17(7): 891–899.-DOI: https://doi.org/10.1634/theoncologist.2012-0039.
Lewis G.D., Xing Y., Haque W., et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun. 2019; 39(1): 60. DOI: https://doi.org/10.1186/s40880-019-0406-4.
Moreno A.C., Lin Y.H., Bedrosian I., et al. Outcomes after treatment of metaplastic versus other breast cancer subtypes. J Cancer. 2020; 11(6): 1341-1350.-DOI: https://doi.org/10.7150/jca.40817.
Wang J., Wei B., Albarracin C.T., et al. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer. 2014; 14: 147.-DOI: https://doi.org/10.1186/1471-2407-14-147.
Arecco L., Borea R., Magaton I.M., et al. Current practices in oncofertility counseling: updated evidence on fertility preservation and post-treatment pregnancies in young women affected by early breast cancer. Expert Rev Anticancer Ther. 2024; 24(9): 803-817.-DOI: https://doi.org/10.1080/14737140.2024.2372337.
ter Welle-Butalid M.E., Vriens I.J.H., Derhaag J.G., et al. Counseling young women with early breast cancer on fertility preservation. J Assist Reprod Genet. 2019; 36: 2593–2604.-DOI: https://doi.org/10.1007/s10815-019-01615-6.
Семиглазова Т.Ю., Понасенко О.И., Лященко В.А., et al. Поздние осложнения лекарственного лечения рака молочной железы: остеопороз, кардиотоксичность, нарушения фертильности (Часть 2). Вопросы онкологии. 2025; 71(1): OF–2029.-DOI: https://doi.org/10.37469/0507-3758-2025-71-1-OF-2029. [Semiglazova T.Yu., Ponasenko O.I., Lyashchenko V.A., et al. Late complications of breast cancer treatment: osteoporosis, cardiotoxicity, fertility disorders (Part 2). Voprosy Onkologii = Problems in Oncology. 2025; 71(1): 17-34.-DOI: https://doi.org/10.37469/0507-3758-2025-71-1-OF-2029 (In Rus)].
Marklund A., Eloranta S., Wikander I., et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study. Hum Reprod. 2020; 35(4): 929–938.-DOI: https://doi.org/10.1093/humrep/deaa029.
Rothé F., Lambertini M., Goldrat O., et al. Circulating tumor DNA to interrogate the safety of letrozole-associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Front Oncol. 2021; 11: 686625.-DOI: https://doi.org/10.3389/fonc.2021.686625.
Park S.Y., Jeong K., Cho E.H., Chung H.W. Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues. Clin Exp Reprod Med. 2021; 48(1): 1-10.-DOI: https://doi.org/10.5653/cerm.2020.03594.
Yamamoto Y., Yamauchi C., Toyama T., et al. The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast Cancer. 2024; 31(3): 340-346.-DOI: https://doi.org/10.1007/s12282-024-01566-6. Epub 2024 Apr 3. Erratum in: Breast Cancer. 2024; 31(4): 736-737.-DOI: https://doi.org/10.1007/s12282-024-01589-z.
Loibl S., Han S.N., Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel). 2012; 7(3): 204-209.-DOI: https://doi.org/10.1159/000339674.
Toesca A., Gentilini O., Peccatori F., et al. Locoregional treatment of breast cancer during pregnancy. Gynecol Surg. 2014; 11(4): 279-284.-DOI: https://doi.org/10.1007/s10397-014-0860-6.
Lambertini M., Kamal N.S., Peccatori F.A., et al. Exploring the safety of chemotherapy for treating breast cancer during pregnancy. Expert Opin Drug Saf. 2015; 14(9): 1395-408.-DOI: https://doi.org/10.1517/14740338.2015.1061500.
Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004; 5(5): 283-291.-DOI: https://doi.org/10.1016/s1470-2045(04)01466-4.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2026